Subcutaneous Drug Delivery Devices Market Share Analysis Report, 2024-2033
The global subcutaneous drug delivery devices market size was estimated at US$ 24.00 billion in 2023 and is expected to reach over US$ 47.88 billion by 2033, poised to grow at a CAGR of 7.15% from 2024 to 2033.
Key Takeaways:
Growth Factors
The growing prevalence of chronic diseases and rising number of vaccinations that extensively utilizes the subcutaneous drug delivery devices like vial are the major factors that drives the growth of the global subcutaneous drug delivery devices market. The growing geriatric population across the globe is expected to foster the demand for the subcutaneous drug delivery devices. This because the geriatric people are more prone to various chronic diseases and frequently needs healthcare support. The healthcare expenditure associated with the old age people are more and hence, the rising number of geriatric people are anticipated to boost the consumption of the subcutaneous drug delivery devices. Moreover, the use of these drug delivery devices is growing because injecting drugs in the body is much more effectives than any other route of administration of drugs. Thus, the global subcutaneous drug delivery devices market is expected to grow at a significant rate during the forecast period.
The world is witnessing a significant rise in the number of patients suffering from numerous chronic diseases such as cancer, autoimmune diseases, respiratory disorders, cardiovascular diseases, diabetes, and various other type of diseases. According to the World Health Organization, the cardiovascular diseases accounts for around 18 million deaths and it is the leading cause of death across the globe. As per the International Agency for Research on Cancer, around 19.3 million new cancer cases were reported in 2023 and this number is expected to reach 28.4 million in 2040, globally. Apart from this, the rapid growth of the biopharmaceutical industry and development of various innovative drugs in the biologics and biosimilar have exponentially supported the growth of the subcutaneous drug delivery devices market. The government authorities like FDA and EMA have played a crucial role in granting approvals to the technologically advanced drug delivery devices that helped the manufacturers to gain consumers’ confidence.
Subcutaneous Drug Delivery Devices Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 25.72 Billion |
| Market Size by 2033 | USD 47.88 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 7.15% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Product, Distribution Channel, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Insulet Corporation, Enable Injections, Amgen, BD, Consort Medical Plc, Ypsomed AG, Eli Lilly, Novo Nordisk, Sanofi, Merck, AstraZeneca |
Segments Insights:
Product Type Insights
Based on the product type, the pen injectors segment dominated the market, accounting for over 37% of the subcutaneous drug delivery devices market share in 2022. This is attributed to the higher social acceptance, increased affordability of the consumers, easy-to-use feature, easy availability, and increased awareness regarding the pen injectors across the globe. The increased product approvals of the pen injectors played a crucial role in its growth. For instance, in April 2023, Sanofi acquired the US FDA approval for its new prefilled pen named Dupixent that serves the asthma, chronic rhinosinusitis, and atopic dermatitis patients at homecare. Moreover, in June 2019, Sanofi acquired the EMA approval for its ToujeoSoloStar Pens in Europe. Therefore, the new product developments and its approval by the government authorities greatly contributed towards the growth of the market.
On the other hand, the wearable injectors is estimated to be the most opportunistic segment during the forecast period. This is attributed to the rising number of needle stick injuries and the higher risks of getting blood-borne diseases associated with the use of injections. The wearable injectors are very efficient at administering the large volume and high-viscosity biologic drugs. Wearable injectors are digital drug delivery devices are offers convenience, and helps the patients to administer accurate doses at right time. These factors are expected to augment the demand for the wearable injectors in the forthcoming future.
Distribution Channel Insights
Based on the distribution channel, the retail pharmacies segment accounted for around 48% of the market share and dominated the global subcutaneous drug delivery devices market in 2023. The subcutaneous drug delivery devices allows the patients to self-administer the drugs as and when required by the patient. The easy availability, wide spread presence of retail pharmacies, increased awareness regarding the subcutaneous drug delivery devices, and increasing health consciousness among the population has augmented the growth of the retail pharmacies segment across the globe. Retail pharmacies are the traditional and the most popular channel for the distribution of medicines and drug delivery device all over the globe, which resulted in its dominance in the market.
On the other hand, the online pharmacies are gaining rapid traction among the consumers. The increased internet penetration and rapidly growing popularity of the online pharmacy platforms is boosting the market growth. The easy to use interface of the online pharmacy platforms, easy payment options, and quick home delivery are the major features provided by the online pharmacies that are expected to boost the growth of the subcutaneous drug delivery devices market.
Subcutaneous Drug Delivery Devices Market Size in the U.S. 2024 to 2033
The U.S. subcutaneous drug delivery devices market size was valued at US$ 25.53 billion in 2023 and is predicted to expand around US$ 56.9 billion by 2033, at a CAGR of 9.3% between 2024 to 2033.
North America dominated the global subcutaneous drug delivery devices market, garnering a market share of over 47% in 2023. The presence of developed healthcare infrastructure, presence of several top manufacturers in the region and the various developmental strategies adopted by them, and increased healthcare expenditure are several prominent factors that drives the growth of the North America subcutaneous drug delivery devices market. Moreover, the increased prevalence of various chronic diseases resulted in the huge demand for drugs and drug delivery devices amongst the population. Around 60% of the US population is suffering from one or more chronic illnesses.
Asia Pacific is estimated to be the most opportunistic segment during the forecast period. This is majorly attributed to the rapidly growing diabetic population in the region owing to the unhealthy food habits of the people. According to the International Diabetes Federation, around 60% of the global diabetic population lives in Asia. Therefore, the market players are expected to shift their focus in the Asia Pacific region. The rising disposable income, growing awareness regarding the diabetes management, and rising healthcare expenditure are the major factors that will drive the growth of the Asia Pacific subcutaneous drug delivery devices market in the forthcoming future.
Key Market Developments
The various developmental strategies like product launches, acquisitions, collaborations, and mergers fosters market growth and offers lucrative growth opportunities to the market players.
Some of the prominent players in the Subcutaneous drug delivery devices market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global subcutaneous drug delivery devices market.
By Product Type
By Distribution Channel
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Subcutaneous Drug Delivery Devices Market
5.1. COVID-19 Landscape: Subcutaneous Drug Delivery Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Subcutaneous Drug Delivery Devices Market, By Product
8.1. Subcutaneous Drug Delivery Devices Market, by Product Type, 2024-2033
8.1.1. Auto-Injectors
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Pen Injectors
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Prefilled Syringes
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Wearable Injectors
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Needle-Free Injectors
8.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Subcutaneous Drug Delivery Devices Market, By Distribution Channel
9.1. Subcutaneous Drug Delivery Devices Market, by Distribution Channel, 2024-2033
9.1.1. Retail Pharmacies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Hospital Pharmacies
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Subcutaneous Drug Delivery Devices Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2021-2033)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product (2021-2033)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product (2021-2033)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2021-2033)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product (2021-2033)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product (2021-2033)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product (2021-2033)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2021-2033)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product (2021-2033)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product (2021-2033)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product (2021-2033)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2021-2033)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product (2021-2033)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product (2021-2033)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product (2021-2033)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2021-2033)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product (2021-2033)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product (2021-2033)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
Chapter 11. Company Profiles
11.1. Insulet Corporation
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Enable Injections
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Amgen
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. BD
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Consort Medical Plc
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Ypsomed AG
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Eli Lilly
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Novo Nordisk
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Sanofi
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Merck
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. AstraZeneca
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers